HCV Advocate News & Pipeline Blog Exclusive
The Liver Meeting – 2015 – Abstract 1204
Abstract Title: IFN-free DAA regimens improve on-treatment quality of life in patients with HIV/HCV coinfection in contrast to previously used PEGIFN/RBV regimens—B Scheiner et al.
The Study Aim and Results
The current study evaluated HIV/hepatitis C coinfected patients for their health related quality-of-life (HRQoL) before, during treatment and when they reached undetectable HCV RNA (viral load) levels. There were 32 HIV/hepatitis C co-infected patients of whom 12 patients were diagnosed as having AIDS (late stages of HIV infection). The study participants were given three health related quality of life (HRQoL) tests that captured fatigue, physical, and mental health impairments. The majority (88%) of the patients had severe fibrosis/cirrhosis. The genotype breakdown was 24 patients with genotype 1, five patients with genotype 3, and three patients with genotype 4. The average age of the participants was 49 years old. The majority of the patients were male (66%). The treatment consisted of sofosbuvir and daclatasvir. At the beginning of the clinical trial all of the HRQoL scores were significantly impaired.
During antiviral therapy (sofosbuvir/daclatasvir) lead to a significant increase in physical health and a reduction in fatigue, but the mental impairment scores did not improve during treatment until week 8 when the HCV RNA became undetectable.
The people who had AIDS, however, had a lower quality of life and a higher degree of fatigue impairment at the beginning of the trail and at mid-treatment compared to those patients in this trail without AIDS.
This is a small but interesting study. It is wonderful that people who do not have AIDS have an improvement in HRQoL during treatment – a far cry from the interferon and ribavirin treatment days.
I am eager to read about this study in a journal that has the final results that show improved HRQoL (and cure rates), and that the people with AIDS have improved health status.
For more information about HIV and hepatitis C coinfection Basics click here... and drill down to many different types of fact sheets
Labels: daclatasvir, HIV/HCV coinfection, HRQoL sofosbuvir